Aurobindo Pharma Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 4,38,151 shares,. Its Average Traded Price (ATP) is ₹1684.75, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 50 @ ₹1682.00.
Aurobindo Pharma has an upper circuit limit of ₹1862.00 and a lower circuit limit of ₹1523.60. The total value traded stands at ₹73.82 CR, and the delivery percentage for the day is 62.68%.
The stock is currently traded with a market lot size of 1. Aurobindo Pharma also offers a dividend yield of 0.24%.
Aurobindo Pharma Share Price Chart
Aurobindo Pharma Share Key Metrics
Volume
4.38 L
Market Cap
96778.56 CR
LTQ@LTP
50@1682.00
ATP
1684.75
Var Margin
14.1 %
Circuit Range
1523.6-1862
Delivery %
62.68 %
Value
73.82 CR
ASM/GSM
No
Market Lot
1
Aurobindo Pharma Resistance and Support
Pivot 1686.13
Resistance
First Resistance
1701.36
Second Resistance
1709.93
Third Resistance
1725.16
Support
First Support
1677.56
Second Support
1662.33
Third Support
1653.76
Aurobindo Pharma Futures & Options
1682
-10.8 (-0.64%)
Aurobindo Pharma Option Chain
View Price, OI, Greeks & More...
27OCT26
1682.90
-15.10 (0.89%)
23NOV26
1689.20
-18.50 (1.08%)
29DEC26
1715.30
0.00 (0.00%)
AUROPHARMA|27OCT26 CE 1680.00
42.35
-9.85 (-18.87%)
AUROPHARMA|27OCT26 PE 1700.00
49.2
6.3 (14.69%)
Aurobindo Pharma Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Aurobindo Pharma Corporate Actions
| Date | Agenda |
|---|---|
| 2026-08-05 | Quarterly Results |
| 2026-05-21 | Audited Results |
| 2026-04-06 | Buy Back of Shares |
| 2026-02-09 | Quarterly Results |
| 2025-11-05 | Quarterly Results |
| 2025-08-04 | Quarterly Results & Interim Dividend |
| 2025-05-26 | Audited Results |
| 2025-02-06 | Quarterly Results |
| 2024-11-09 | Quarterly Results |
| 2024-08-10 | Quarterly Results |
| Ex Date | Record Date | |
|---|---|---|
| 2025-08-08 | 2025-08-08 | View More |
| Buyback Period | ||
|---|---|---|
| 5 Aug - 09 Aug 24 12.30 pm | View More |
Aurobindo Pharma News
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aurobindo Pharma has received final approval from the USFDA to manufacture and market Perampanel Tablets. The approved product has an estimated market size of US$ 67 million and is scheduled for commercial launch in Q3 FY27.
Oct 03 2026 17:09:24
Aurobindo Pharma Ltd - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Aurobindo Pharma's wholly-owned subsidiary Apitoria has completed the acquisition of an 80% stake in A1 Biochem Labs' Contract Research Services business. The move grants access to a CRO platform with over 50 clients and 800 completed projects.
Oct 02 2026 18:35:03
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition
Aurobindo Pharma's wholly-owned step-down subsidiary, A1 USA Inc, has acquired a 100% stake in A1 Biochem Labs LLC for a cash consideration of USD 15.24 million. The acquisition will help the company create a dedicated Contract Research, Development and Manufacturing (CRDMO) platform.
Oct 02 2026 18:09:31
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Acquisition
Aurobindo Pharma announced that its step-down subsidiary A1 Labs allotted a 20% stake to former promoter Dr. Rajendra Gadikota for Rs.33.80 crores. Apitoria Pharma now holds an 80% stake in the entity, with an option to acquire the remaining 20% in the future.
Oct 01 2026 12:54:26
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aurobindo Pharma's subsidiary Acrotech Biopharma launched ADQUEY (difamilast 1%) ointment in the U.S. market for atopic dermatitis. The product will compete in a dermatology market estimated at $1.3 billion for the 12 months ending July 2026.
Sep 30 2026 21:28:49
Aurobindo Pharma Ltd - 524804 - Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, completed a US FDA inspection of its Unit-II API manufacturing facility. The inspection concluded with a single procedural observation, which the company will address.
Sep 15 2026 18:14:22
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Aurobindo Pharma has received final USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg and 80 mcg). This marks the company's first metered-dose inhaler (MDI) product, strengthening its presence in complex respiratory therapies. The US market for the reference product was $301 million.
Sep 15 2026 13:10:33
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Aurobindo Pharma will participate in the J. P. Morgan India Investor Conference in Mumbai on September 22, 2026. Company officials will engage in one-on-one and group meetings. No unpublished price sensitive information will be discussed.
Sep 11 2026 16:37:16
Aurobindo Pharma Management
| Name | Position |
|---|---|
| Mangalam Ramasubramanian Kumar | Chairman |
| K Nityananda Reddy | Vice Chairman & Managing Director |
Aurobindo Pharma Similar Stocks
Zydus Lifesciences Ltd.
1153.00
-6.50 (0.56%)
Cipla Ltd.
1327.20
-13.00 (0.97%)
Laurus Labs Ltd.
2052.80
2.80 (0.14%)
Mankind Pharma Ltd.
2500.00
0.00 (0.00%)
Dr. Reddy's Laboratories Ltd.
1203.80
-4.20 (0.35%)
Lupin Ltd.
2012.90
-16.40 (0.81%)
Max Healthcare Institute Ltd.
908.00
5.50 (0.61%)
Manipal Health Enterprises Ltd.
699.15
8.65 (1.25%)
Glenmark Pharmaceuticals Ltd.
2282.30
-28.70 (1.24%)
Alkem Laboratories Ltd.
5350.50
58.50 (1.11%)
Aurobindo Pharma FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in AUROPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in AUROPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade